ArticleBlood neoplasia2026
Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.Dermatology and therapy · 2026Article
- PIM1 in myeloproliferative neoplasms: potential pathogenic and therapeutic implications.Leukemia · 2026Review
- MDI1228, a topical pan-JAK inhibitor, disrupts dermal fibroblast-T cell chemokine crosstalk to resolve allergic contact and atopic dermatitis.Frontiers in immunology · 2026Article
- Fedratinib in 2025 and beyond: indications and future applications.Blood advances · 2025Review
- Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.Annals of hematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Four Janus kinase inhibitors (JAKinibs), ruxolitinib, fedratinib, pacritinib, and momelotinib, are indicated for myelofibrosis. All inhibit JAK2, but effects on additional kinases vary markedly, shaping their specific clinical pharmacology. Published comparative inhibitory profiles and cellular pharmacology data are incomplete and were determined here. Inhibitory potency and relative selectivity of JAKinibs were determined by full kinome profiling. JAKinib effects on signaling and cell growth were measured using JAK2-dependent and JAK2-independent cell lines. Ruxolitinib was the most potent JAK2 inhibitor (half-maximal inhibitory concentration [IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.